Deciphering GenomeDx

While some investors are fleeing the diagnostic space, a series B round for GenomeDx Biosciences Inc. shows there is money out there for companies with a path to reimbursement.

The size of the round is undisclosed. It was led by Merck Global Health Innovation Fund (GHIF) and another new investor that was not disclosed. Existing investors Baird Venture Partners, Aeris Capital and CD Ventures participated...